Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Busulfan (DB01008)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00134017Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerTreatment
NCT00002792Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative DisordersTreatment
NCT00004181Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid MetaplasiaTreatment
NCT00006367Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With MyelofibrosisTreatment
NCT00005797Bone Marrow Transplant in Treating Patients With Hematologic CancersTreatment
NCT00346359Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerTreatment
NCT00806767Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerTreatment